Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Shionogi

Drug and asset intelligence for Shionogi with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 3
Stage: Development stage unavailable

Recent signals(4)

RegulatoryJuly 22, 2026

FDA Accepts Application for XOCOVA (Ensitrelvir) by Shionogi

The FDA has accepted the New Drug Application for XOCOVA, an antiviral drug containing Ensitrelvir.

ClinicalJuly 18, 2026

Shionogi's S-892216 Study Targets Renal Impairment Pharmacokinetics

A study is underway to assess the pharmacokinetics, safety, and tolerability of S-892216 in patients with varying degrees of renal impairment.

RegulatoryJuly 10, 2026

FDA Acceptance of Supplemental NDA for FETROJA by Shionogi

The FDA has accepted a supplemental NDA for FETROJA (cefiderocol sulfate tosylate) from Shionogi.

ClinicalJuly 8, 2026

Shionogi's S-337395 Trial Targets High-Risk RSV Patients

A clinical trial is underway to evaluate the antiviral efficacy of S-337395 in nonhospitalized adults at high risk for severe RSV.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(3)

Topline Data

— Shionogi

July 18, 2026 · N/A

Topline Data

— Shionogi

July 10, 2026 · N/A

Topline Data

— Shionogi

July 8, 2026 · N/A

Indications

Infectious Disease →

Therapeutic areas

Infectious Disease →

Infectious Disease · Antibiotic →

Infectious Disease · Respiratory Syncytial Virus →

Nephrology · Pharmacokinetics →

Pharmacokinetics →

Respiratory Syncytial Virus →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.